within Pharmacolibrary.Drugs.ATC.L;

model L01FX12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.29 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tafasitamab is a humanized monoclonal antibody targeting CD19, used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is FDA approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for patients with relapsed or refractory DLBCL receiving tafasitamab intravenously. PK parameters are for adult patients as described in registration trials and FDA/EMA assessment reports.</p><h4>References</h4><ol><li><p>Hoy, SM (2020). Tafasitamab: First Approval. <i>Drugs</i> 80(16) 1731â€“1737. DOI:<a href=&quot;https://doi.org/10.1007/s40265-020-01405-w&quot;>10.1007/s40265-020-01405-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32946059/&quot;>https://pubmed.ncbi.nlm.nih.gov/32946059</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FX12;
